ELITE PHARMACEUTICAL
ELI
ELI was delisted on the 20th of May, 2009.
1 hedge funds and large institutions have $7.69K invested in ELITE PHARMACEUTICAL in 2023 Q3 according to their latest regulatory filings, with 1 funds opening new positions, increasing their positions, reducing their positions, and 0 closing their positions.
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fisher Asset Management
Camas,
Washington
|
+$7.69K |
Top Sellers
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
Fisher Asset Management
Camas,
Washington
| $7.69K | +$7.69K | +82,000 | New |
|
ELI Hedge Fund Activity: Q3 2023 in Review
1 of the 6,301 institutional investors tracked by Wall St. Rank reported a position in ELITE PHARMACEUTICAL (ELI) for Q3 2023, worth a combined $7.69K.
Buyers outnumbered sellers: 1 fund opened new ELI positions and 0 closed out — a net gain of 1 holder — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Fisher Asset Management, opening a new position worth an estimated $7.69K.
- 1 institutional investor held ELITE PHARMACEUTICAL (ELI) as of Q3 2023, up from 0 in Q2 2023.
- Funds reported $7.69K of ELITE PHARMACEUTICAL stock for Q3 2023.
- 1 fund opened new ELITE PHARMACEUTICAL positions in Q3 2023 and 0 closed out, a net change of +1 holder.
- The largest ELITE PHARMACEUTICAL buyer in Q3 2023 was Fisher Asset Management, an estimated $7.69K added.
Based on aggregated 13F filings for Q3 2023.